For this purpose, CSF levels of tau, Aβ42, Aβ1–42%, and Aβ1–40ox% were determined in CSF of 45 patients with probable AD, 15 with probable DLB, 21 with PDD and 40 nondemented disease controls (NDC). This evidence concerns the gene MAPT and Lewy body dementia.